

091-206758

For Internal Use  
Only  
Sec File No. 9-

Submit 1 Original  
and 9 Copies

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0504
Expires: August 31, 2010
Estimated average burden hours per response.....3.60

FORM 19b-4(e)

Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM  
SLC  
Mail Processing  
Section

Part I

Initial Listing Report

MAY 18 2016

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:  
**NASDAQ OMX PHLX LLC (traded pursuant to unlisted trading privileges)**

Washington DC

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):  
**Open End Management Investment Company**

412

3. Class of New Derivative Securities Product:  
**Exchange Traded Fund**



4. Name of Underlying Instrument:  
**INDXX Global Health & Wellness Index**

16000622

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:  
**Broad-based**

6. Ticker Symbol(s) of New Derivative Securities Product:  
**LNGR**

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:

**Listed on: Australian Stock Exchange (ASX), Deutsche Borse, Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris, Hong Kong, Irish Stock Exchange, Korea Stock Exchange, La Borsa Valoria Italiana, London Stock Exchange, Mercado Continuo Espanol, NASDAQ Stock Market LLC, NYSE, New Zealand, OMX Nordic Exchange, Copenhagen, OMX Nordic Exchange, Helsinki, OMX Nordic Exchange, Stockholm, Oslo Stock Exchange, SWS Swiss, Singapore Stock Exchange, Tel Aviv Stock Exchange, Tokyo Stock Exchange, Toronto, Vienna**

8. Position Limits of New Derivative Securities Product (if applicable):  
**Regular way trades settle on T + 3 (cash settled)**

9. Position Limits of New Derivative Securities Product (if applicable):  
**N/A**

Part II

Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:  
**Colleen Steele**

Title:  
**Assistant Corporate Secretary**

Telephone Number:  
**301-978-8736**

Manual Signature of Official Responsible for Form:

Date: **May 13, 2016**

Section **19b-4**  
Rule **19b-4(e)**

Public  
Availability: **MAY 18 2016**

SECURITIES AND EXCHANGE COMMISSION  
**RECEIVED**  
MAY 18 2016  
DIVISION OF TRADING & MARKETS